[go: up one dir, main page]

MX9604400A - Diagnostico, terapia y modelos celular y animal para enfermedades asociadas con defectos mitocondriales. - Google Patents

Diagnostico, terapia y modelos celular y animal para enfermedades asociadas con defectos mitocondriales.

Info

Publication number
MX9604400A
MX9604400A MX9604400A MX9604400A MX9604400A MX 9604400 A MX9604400 A MX 9604400A MX 9604400 A MX9604400 A MX 9604400A MX 9604400 A MX9604400 A MX 9604400A MX 9604400 A MX9604400 A MX 9604400A
Authority
MX
Mexico
Prior art keywords
mitochondrial
methods
disease
cybrid
therapy
Prior art date
Application number
MX9604400A
Other languages
English (en)
Inventor
Corina Herrnstadt
William David Parker
Robert E Davis
Scott William Miller
Original Assignee
Mitokor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/219,842 external-priority patent/US5565323A/en
Priority claimed from US08/397,808 external-priority patent/US5888498A/en
Application filed by Mitokor filed Critical Mitokor
Publication of MX9604400A publication Critical patent/MX9604400A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0053—Oxidoreductases (1.) acting on a heme group of donors (1.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)

Abstract

La presente invencion se relaciona con las mutaciones genéticas en los genes de la citocromo c oxidasa mitocondrial que se agregan con la enfermedad de Alzheimer (AD), diabetes mellitus, enfermedad de Parkinson y otras enfermedades de origen mitocondrial. La invencion proporciona los métodos para detectar esas mutaciones, ya sea antes o después de la aparicion de los síntomas clínicos. La invencion proporciona además el tratamiento de la disfuncion de la citocromo c oxidasa. También se describen las líneas celulares cíbridas que tiene utilidad como sistemas modelos para el estudio de los padecimientos que están asociados con los defectos mitocondriales. Los cibridos se construyen mediante el tratamiento de líneas celulares inmortales con un agente que desactiva irreversiblemente el transporte mitocondrial de electrones, y transfectado a continuacion las células con mitocondrías aisladas de muestras de tejido enfermo. Uno de tales cibridos se construyo usando células de neurobalstoma y mitocondrías de un paciente que padecía la Enfermedad de Alzheimer. También se proporcionan los métodos para usar tales cibridos para seleccionar los fármacos u terapias utiles en el tratamiento de tales padecimientos. Además, también se proporcionan animales cibrido, los métodos de produccion de ellos y los métodos para usarlos en la seleccion del fármaco y la terapia.
MX9604400A 1994-03-30 1995-03-30 Diagnostico, terapia y modelos celular y animal para enfermedades asociadas con defectos mitocondriales. MX9604400A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/219,842 US5565323A (en) 1994-03-30 1994-03-30 Cytochrome oxidase mutations aiding diagnosis of sporadic alzheimer's disease
US08/397,808 US5888498A (en) 1995-03-03 1995-03-03 Cellular and animal models for diseases associated with mitochondrial defects
PCT/US1995/004063 WO1995026973A1 (en) 1994-03-30 1995-03-30 Diagnosis, therapy and cellular and animal models for diseases associated with mitochondrial defects

Publications (1)

Publication Number Publication Date
MX9604400A true MX9604400A (es) 1997-12-31

Family

ID=26914309

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9604400A MX9604400A (es) 1994-03-30 1995-03-30 Diagnostico, terapia y modelos celular y animal para enfermedades asociadas con defectos mitocondriales.

Country Status (12)

Country Link
US (1) US20010021526A1 (es)
EP (1) EP0751951A4 (es)
JP (1) JPH09511398A (es)
CN (1) CN1150433A (es)
AU (1) AU705230B2 (es)
BR (1) BR9507241A (es)
CA (1) CA2186636A1 (es)
FI (1) FI963884A (es)
MX (1) MX9604400A (es)
NO (1) NO964073L (es)
NZ (1) NZ283660A (es)
WO (1) WO1995026973A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115364B1 (en) 1993-10-26 2006-10-03 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6027880A (en) 1995-08-02 2000-02-22 Affymetrix, Inc. Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
US20060229824A1 (en) 1993-10-26 2006-10-12 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes
US5840493A (en) * 1994-03-30 1998-11-24 Mitokor Mitochondrial DNA mutations that segregate with late onset diabetes mellitus
US6291172B1 (en) * 1995-03-03 2001-09-18 Mitokor Diagnostic assay for diabetes mellitus based on mutational burden
AU5296496A (en) * 1995-03-24 1996-10-16 Mitokor Mutation detection by differential primer extension of mutant and wildtype target sequences
US6391550B1 (en) 1996-09-19 2002-05-21 Affymetrix, Inc. Identification of molecular sequence signatures and methods involving the same
GB9620028D0 (en) 1996-09-26 1996-11-13 Ludwig Inst Cancer Res Factors which interact with oncoproteins
WO1999055845A1 (en) * 1998-04-28 1999-11-04 Mitokor Cellular and animal models for diseases associated with altered mitochondrial function
US6441149B1 (en) * 1998-06-15 2002-08-27 Mitokor Diagnostic method based on quantification of extramitochondrial DNA
US6489095B2 (en) 1998-06-15 2002-12-03 Mitokor Diagnostic method based on quantification of extramitochondrial DNA
MXPA01008549A (es) * 1999-02-23 2003-06-06 Pro Neuron Inc Metodos de tratamiento de desordenes mitocondriales.
AU3900600A (en) * 1999-03-16 2000-10-04 Mitokor Differential expression of organellar gene products
FR2798556B1 (fr) * 1999-09-17 2004-02-27 Aventis Pharma Sa Nouveau modele animal de la maladie d'alzheimer presentant a la fois des plaques amyloides et des dysfonctionnements mitochondriaux
CA2384865A1 (fr) * 1999-09-17 2001-03-29 Aventis Pharma S.A. Nouveau modele animal de la maladie d'alzheimer presentant a la fois des plaques amyloides et des dysfonctionnements mitochondriaux
CN1277995A (zh) * 1999-11-22 2000-12-27 上海博容基因开发有限公司 一种新的多肽——人细胞色素氧化酶相关蛋白37和编码这种多肽的多核苷酸
CN1322143C (zh) * 2000-12-04 2007-06-20 普里马根公司 检测线粒体核酸与核基因核酸比率确定药物活性和/或副作用的方法
JP2003116576A (ja) * 2001-10-17 2003-04-22 Gifu International Institute Of Biotechnology ヒトミトコンドリアｄｎａを用いた遺伝子検出方法
US7888334B2 (en) 2003-08-22 2011-02-15 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
US7888335B2 (en) 2003-08-22 2011-02-15 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
JP2008535945A (ja) * 2005-03-09 2008-09-04 セファイド 極性色素
EP2641617A1 (en) 2007-05-02 2013-09-25 THE McLEAN HOSPITAL CORPORATION Methods and compositions for mitochondrial replacement therapy
WO2013035101A1 (en) 2011-09-11 2013-03-14 Minovia Therapeutics Ltd. Compositions of functional mitochondria and uses thereof
ES2665522T3 (es) * 2012-10-05 2018-04-26 Neurovive Pharmaceutical Ab Prueba de toxicidad mitocondrial
KR101556439B1 (ko) 2013-07-01 2015-10-15 서울대학교산학협력단 미토콘드리아 역행성 신호 경로와 관련된 ＲＸＲα의 기능 및 용도
JP7395355B2 (ja) 2017-05-08 2023-12-11 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド 膜融合を促進するための組成物およびその使用
CN107746889A (zh) * 2017-07-17 2018-03-02 国家海洋局北海环境监测中心 用于扩增底栖多毛类环节动物线粒体co i基因片段的引物
US11951135B2 (en) 2018-07-22 2024-04-09 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of muscle diseases
WO2020054829A1 (ja) * 2018-09-14 2020-03-19 ルカ・サイエンス株式会社 ミトコンドリアのリンパ器官への移植およびそのための組成物
CN109796527B (zh) * 2019-03-07 2020-09-04 广西大学 一种红麻线粒体蛋白cox3抗原多肽及制备多克隆抗体的方法和应用
CN111034736B (zh) * 2019-12-13 2021-04-06 西北农林科技大学 一种杀虫组合物及其应用
CN111579763B (zh) * 2020-04-09 2023-04-07 北京博瑞世安科技有限公司 检测白细胞线粒体呼吸功能的方法及检测肾阴虚症的方法
CN111781175B (zh) * 2020-06-18 2023-04-21 中国人民解放军军事科学院国防科技创新研究院 一种用于提高细胞中线粒体活性的方法及装置和应用
WO2024015951A2 (en) * 2022-07-15 2024-01-18 Seq Biomarque, Llc Methods and materials for identifying biomarkers and/or pathways associated with alzheimer's disease
CN115960087B (zh) * 2022-09-16 2024-06-07 浙江工业大学 黏度响应型双光子荧光化合物及其合成与应用
CN117384269B (zh) * 2023-09-21 2024-06-18 南方医科大学南方医院 短肽mfrlp及其在制备动脉重塑相关疾病药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185244A (en) * 1989-12-08 1993-02-09 Emory University Genetic test for hereditary neuromuscular disease
US5296349A (en) * 1990-06-14 1994-03-22 Emory University Molecular genetic test for myoclonic epilepsy
US5494794A (en) * 1992-10-20 1996-02-27 Emory University Detection of mitochondrial DNA mutations associated with Alzheimer's disease and Parkinson's disease
US5506101A (en) * 1993-06-30 1996-04-09 Cedars-Sinai Medical Center Method for detection of susceptibility mutations for ototoxic deafness

Also Published As

Publication number Publication date
EP0751951A4 (en) 2000-05-03
AU705230B2 (en) 1999-05-20
JPH09511398A (ja) 1997-11-18
CN1150433A (zh) 1997-05-21
NO964073L (no) 1996-11-29
US20010021526A1 (en) 2001-09-13
NZ283660A (en) 1998-07-28
CA2186636A1 (en) 1995-10-12
AU2204295A (en) 1995-10-23
WO1995026973A1 (en) 1995-10-12
NO964073D0 (no) 1996-09-27
FI963884A0 (fi) 1996-09-27
FI963884A (fi) 1996-11-26
BR9507241A (pt) 1997-09-16
EP0751951A1 (en) 1997-01-08

Similar Documents

Publication Publication Date Title
MX9604400A (es) Diagnostico, terapia y modelos celular y animal para enfermedades asociadas con defectos mitocondriales.
Bendotti et al. Early vacuolization and mitochondrial damage in motor neurons of FALS mice are not associated with apoptosis or with changes in cytochrome oxidase histochemical reactivity
Fidziańska et al. Ultrastructural abnormality of sarcolemmal nuclei in Emery-Dreifuss muscular dystrophy (EDMD)
Hefter et al. Amyloid, APP, and electrical activity of the brain
Grealish et al. The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson’s disease
Maphis et al. Loss of tau rescues inflammation-mediated neurodegeneration
Mercerón-Martínez et al. Alzheimer’s disease, neural plasticity, and functional recovery
Evans et al. Chemical characterization of a hormone that promotes cell arrest in G2 in complex tissues
Norgren Jr et al. Herpes simplex virus as a transneuronal tracer
Campolongo et al. Systemic administration of substance P recovers beta amyloid-induced cognitive deficits in rat: involvement of Kv potassium channels
WO2005046570A3 (en) Human stem cell materials and methods
Di Castro et al. Astrocyte control of the entorhinal cortex‐dentate gyrus circuit: Relevance to cognitive processing and impairment in pathology
Gordon et al. Intrahippocampal pathways involved in learning/memory mechanisms are affected by intracerebral infusions of amyloid-β25-35 peptide and hydrated fullerene C60 in rats
Au et al. A small molecule M1 promotes optic nerve regeneration to restore target-specific neural activity and visual function
Wang et al. Oligodendrocyte lineage cells: advances in development, disease, and heterogeneity
Mikkelsen et al. (6; 15) Translocation with loss of chromosome material in the patient and various chromosome aberrations in family members
Buonvicino et al. Early derangement of axonal mitochondria occurs in a mouse model of progressive but not relapsing-remitting multiple sclerosis
WO2000066782A3 (en) Diagnostic assay for diabetes mellitus based on mutational burden
AU2256097A (en) A g protein-coupled receptor with an enlarged extracellular domain
US7087581B1 (en) Method for the treatment of diseases or disorders of the inner ear
Arango-Gonzalez et al. Inhibition of VCP preserves retinal structure and function in autosomal dominant retinal degeneration
Sonsalla et al. Chronic intraventricular administration of 1-methyl-4-phenylpyridinium as a progressive model of Parkinson's disease
WO2000042166A3 (en) Methods and compositions for monitoring cellular processing of epitope-tagged beta-amyloid precursor protein
DeGiorgio et al. Neurotoxic APP C-terminal and β-amyloid domains colocalize in the nuclei of substantia nigra pars reticulata neurons undergoing delayed degeneration
Critchley et al. Fatigue and melatonin in Parkinson's disease

Legal Events

Date Code Title Description
FA Abandonment or withdrawal